Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Transl Psychiatry ; 4: e342, 2014 Jan 07.
Artículo en Inglés | MEDLINE | ID: mdl-24399045

RESUMEN

Ketamine is a unique anesthetic reagent known to produce various psychotic symptoms. Ketamine has recently been reported to elicit a long-lasting antidepressant effect in patients with major depression. Although recent studies provide insight into the molecular mechanisms of the effects of ketamine, the antidepressant mechanism has not been fully elucidated. To understand the involvement of the brain serotonergic system in the actions of ketamine, we performed a positron emission tomography (PET) study on non-human primates. Four rhesus monkeys underwent PET studies with two serotonin (5-HT)-related PET radioligands, [(11)C]AZ10419369 and [(11)C]DASB, which are highly selective for the 5-HT1B receptor and serotonin transporter (SERT), respectively. Voxel-based analysis using standardized brain images revealed that ketamine administration significantly increased 5-HT1B receptor binding in the nucleus accumbens and ventral pallidum, whereas it significantly reduced SERT binding in these brain regions. Fenfluramine, a 5-HT releaser, significantly decreased 5-HT1B receptor binding, but no additional effect was observed when it was administered with ketamine. Furthermore, pretreatment with 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX), a potent antagonist of the glutamate α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor, blocked the action of ketamine on the 5-HT1B receptor but not SERT binding. This indicates the involvement of AMPA receptor activation in ketamine-induced alterations of 5-HT1B receptor binding. Because NBQX is known to block the antidepressant effect of ketamine in rodents, alterations in the serotonergic neurotransmission, particularly upregulation of postsynaptic 5-HT1B receptors in the nucleus accumbens and ventral pallidum may be critically involved in the antidepressant action of ketamine.


Asunto(s)
Antidepresivos/farmacología , Prosencéfalo Basal/metabolismo , Antagonistas de Aminoácidos Excitadores/farmacología , Ketamina/farmacología , Núcleo Accumbens/metabolismo , Receptor de Serotonina 5-HT1B/metabolismo , Receptores AMPA/metabolismo , Proteínas de Transporte de Serotonina en la Membrana Plasmática/metabolismo , Animales , Antidepresivos/administración & dosificación , Prosencéfalo Basal/efectos de los fármacos , Radioisótopos de Carbono/farmacocinética , Antagonistas de Aminoácidos Excitadores/administración & dosificación , Fenfluramina/administración & dosificación , Fenfluramina/farmacología , Ketamina/administración & dosificación , Macaca , Masculino , Núcleo Accumbens/efectos de los fármacos , Tomografía de Emisión de Positrones , Quinoxalinas/administración & dosificación , Quinoxalinas/farmacología , Receptores AMPA/antagonistas & inhibidores
2.
Antimicrob Agents Chemother ; 39(1): 260-3, 1995 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-7535038

RESUMEN

The beta-lactamase gene from Streptomyces fradiae Y59 was cloned and sequenced. To determine which amino acid residues are critical in binding activity to blue dextran, chimera beta-lactamases were constructed and their binding abilities were determined. The results suggested that blue dextran binding may depend more on overall conformation of about two-thirds of the beta-lactamase molecule from the N terminus than on the primary structure.


Asunto(s)
Streptomyces/genética , beta-Lactamasas/genética , Secuencia de Aminoácidos , Secuencia de Bases , Clonación Molecular , Dextranos/metabolismo , Datos de Secuencia Molecular , Mutagénesis Sitio-Dirigida , beta-Lactamasas/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...